Exciting Collaboration Between Zealand Pharma and Roche
Zealand Pharma A/S has reached a significant milestone by finalizing its collaboration and license agreement with Roche, a move widely anticipated in the biotechnology sector. The partnership marks a turning point in Zealand Pharma's mission to be a leader in innovative peptide-based therapies, especially in the management of obesity.
Partnership Highlights
With all closing conditions satisfied, including necessary regulatory requirements, the collaboration is now officially in effect. Zealand Pharma's CEO, Adam Steensberg, expressed enthusiasm about the partnership, highlighting that Roche meets all expectations the company had in a collaborative partner. The aim is not just to introduce petrelintide, a notable drug candidate, to the market, but to maximize its potential benefits for those dealing with overweight or obesity challenges.
Focus on Obesity Management
This strategic alliance offers new pathways for Zealand Pharma as it focuses on addressing the growing global concern of obesity. With innovative peptide medicines like petrelintide, the company is determined to make a meaningful difference in the lives of those who need it most. As clinical trials progress and the partnership unfolds, both companies are dedicated to unlocking the full therapeutic potential of their combined expertise.
About Zealand Pharma
Founded in 1998, Zealand Pharma is rooted in innovation, dedicated to discovering and developing peptide-based medicines. The company has successfully advanced over ten drug candidates into clinical development, with two already available on the market and multiple candidates in late-stage trials. This rich history of innovation underscores Zealand Pharma's commitment to addressing significant medical needs.
Company Growth and Future Outlook
The company operates with a vision to extend its reach both in Europe and the United States, collaborating with various pharmaceutical entities to enhance its market presence. Zealand stands out for its substantial pipeline and ongoing development efforts, which reflect a robust strategy for future growth in the competitive biotech landscape.
Contact Information
For inquiries, you can reach Adam Lange, Vice President of Investor Relations, at Zealand Pharma. He can be contacted via the email address provided. For questions regarding investor relations, Neshat Ahmadi is also available to assist. Finally, Anna Krassowska, PhD, handles both investor communications and media queries, ensuring that stakeholders receive timely and relevant information.
Frequently Asked Questions
What is the purpose of the collaboration between Zealand Pharma and Roche?
The collaboration aims to advance the development of innovative peptide-based medicines, with a particular focus on managing obesity through the use of the drug candidate petrelintide.
What are peptide-based medicines?
Peptide-based medicines are therapies that utilize peptides—short chains of amino acids—to treat diseases. They can be effective in various therapeutic areas, including metabolism and obesity.
What is the significance of petrelintide?
Petrelintide is a promising drug candidate in Zealand Pharma's portfolio that aims to help individuals with overweight or obesity challenges, reflecting the company's commitment to addressing significant health concerns.
When did Zealand Pharma announce this collaboration?
The announcement regarding the collaboration was made on March 12, 2025, and all necessary closing conditions were subsequently met to move forward.
How does Zealand Pharma plan to utilize this partnership?
Zealand Pharma plans to work closely with Roche to maximize the potential of their collaborative efforts, targeting the development and commercialization of effective therapies for obesity management.
